Christian Meier
Research Subjects
Christian Meier has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Jean-Jacques Staub
2 shared publicationsMerih Guglielmetti
2 shared publicationsAndré R. Miserez
Divisions of Endocrinology (C.M., J.J.S., C.B.R., M.G., M.K., A.R.M., B.M.), CH-4031 Basel, Switzerland
1 shared publicationBeat Müller
Divisions of Endocrinology (C.M., J.J.S., C.B.R., M.G., M.K., A.R.M., B.M.), CH-4031 Basel, Switzerland
1 shared publicationBeat Müller
1 shared publicationCarl-Bénédict Roth
Divisions of Endocrinology (C.M., J.J.S., C.B.R., M.G., M.K., A.R.M., B.M.), CH-4031 Basel, Switzerland
1 shared publication
Latest Publications
Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with overt primary thyroid failure: cross sectional survey
We recruited 49 patients with overt hypothyroidism (TSH >20 mU/l, free thyroxine –3 To estimate the association between thyroid hormones and markers of tissue hypothyroidism we correlated TSH and thyroid hormone concentrations with the different tissue parameters. The ethics committee for human studies approved the study.
Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with overt primary thyroid failure: cross sectional survey
We recruited 49 patients with overt hypothyroidism (TSH >20 mU/l, free thyroxine –3 To estimate the association between thyroid hormones and markers of tissue hypothyroidism we correlated TSH and thyroid hormone concentrations with the different tissue parameters. The ethics committee for human studies approved the study.
- 23 May 2002
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 127 (21) , 1145-1150
Mental changes in hypo- and hyperthyroidism
Psychiatrische Auffälligkeiten bei Patienten mit Schilddrüsenfunktionsstörungen können sehr vielgestaltig sein. So werden häufig kognitive Funktionsstörungen und depressive Zustandsbilder, seltener Angststörungen sowie psychotische Zustände mit Wahnvorstellungen und Halluzinationen beschrieben. Wie aus Fallsammlungen bekannt kann sich eine Hypo- bzw. Hyperthyreose alleine durch diese psychischen Veränderungen manifestieren, ohne dass typisch organisch geprägte Symptome bestehen müssen. Um eine zugrundeliegende Schilddrüsenerkrankung frühzeitig erkennen und gezielt behandeln zu können, ist die Kenntnis psychischer Manifestationsformen erforderlich. Diese Übersicht soll die psychiatrischen Manifestationen bei Patienten mit Schilddrüsenfunktionsstörungen erläutern und deren diagnostische Abgrenzung zu primär psychiatrischen Erkrankungen aufzeigen.
- 23 May 2002
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 127 (21) , 1145-1150
Mental changes in hypo- and hyperthyroidism
Psychiatrische Auffälligkeiten bei Patienten mit Schilddrüsenfunktionsstörungen können sehr vielgestaltig sein. So werden häufig kognitive Funktionsstörungen und depressive Zustandsbilder, seltener Angststörungen sowie psychotische Zustände mit Wahnvorstellungen und Halluzinationen beschrieben. Wie aus Fallsammlungen bekannt kann sich eine Hypo- bzw. Hyperthyreose alleine durch diese psychischen Veränderungen manifestieren, ohne dass typisch organisch geprägte Symptome bestehen müssen. Um eine zugrundeliegende Schilddrüsenerkrankung frühzeitig erkennen und gezielt behandeln zu können, ist die Kenntnis psychischer Manifestationsformen erforderlich. Diese Übersicht soll die psychiatrischen Manifestationen bei Patienten mit Schilddrüsenfunktionsstörungen erläutern und deren diagnostische Abgrenzung zu primär psychiatrischen Erkrankungen aufzeigen.
- Open Access
- 1 October 2001
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 86 (10) , 4860-4866
TSH-Controlled L-Thyroxine Therapy Reduces Cholesterol Levels and Clinical Symptoms in Subclinical Hypothyroidism: A Double Blind, Placebo-Controlled Trial (Basel Thyroid Study)
This study evaluated the effect of physiological, TSH-guided, l-thyroxine treatment on serum lipids and clinical symptoms in patients with subclinical hypothyroidism. Sixty-six women with proven subclinical hypothyroidism (TSH, 11.7 ± 0.8 mIU/liter) were randomly assigned to receive l-thyroxine or placebo for 48 wk. Individual l-thyroxine replacement (mean dose, 85.5 ± 4.3 μg/d) was performed based on blinded TSH monitoring, resulting in euthyroid TSH levels (3.1 ± 0.3 mIU/liter). Lipid concentrations and clinical scores were measured before and after treatment. Sixty-three of 66 patients completed the study. In the l-thyroxine group (n = 31) total cholesterol and low density lipoprotein cholesterol were significantly reduced [−0.24 mmol/liter, 3.8% (P = 0.015) and −0.33 mmol/liter, 8.2% (P = 0.004), respectively]. Low density lipoprotein cholesterol decrease was more pronounced in patients with TSH levels greater than 12 mIU/liter or elevated low density lipoprotein cholesterol levels at baseline. A significant decrease in apolipoprotein B-100 concentrations was observed (P = 0.037), whereas high density lipoprotein cholesterol, triglycerides, apolipoprotein AI, and lipoprotein(a) levels remained unchanged. Two clinical scores assessing symptoms and signs of hypothyroidism (Billewicz and Zulewski scores) improved significantly (P = 0.02). This is the first double blind study to show that physiological l-thyroxine replacement in patients with subclinical hypothyroidism has a beneficial effect on low density lipoprotein cholesterol levels and clinical symptoms of hypothyroidism. An important risk reduction of cardiovascular mortality of 9–31% can be estimated from the observed improvement in low density lipoprotein cholesterol.
- 1 October 2001
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 86 (10) , 4860-4866
Open AccessTSH-Controlled L-Thyroxine Therapy Reduces Cholesterol Levels and Clinical Symptoms in Subclinical Hypothyroidism: A Double Blind, Placebo-Controlled Trial (Basel Thyroid Study)
This study evaluated the effect of physiological, TSH-guided, l-thyroxine treatment on serum lipids and clinical symptoms in patients with subclinical hypothyroidism. Sixty-six women with proven subclinical hypothyroidism (TSH, 11.7 ± 0.8 mIU/liter) were randomly assigned to receive l-thyroxine or placebo for 48 wk. Individual l-thyroxine replacement (mean dose, 85.5 ± 4.3 μg/d) was performed based on blinded TSH monitoring, resulting in euthyroid TSH levels (3.1 ± 0.3 mIU/liter). Lipid concentrations and clinical scores were measured before and after treatment. Sixty-three of 66 patients completed the study. In the l-thyroxine group (n = 31) total cholesterol and low density lipoprotein cholesterol were significantly reduced [−0.24 mmol/liter, 3.8% (P = 0.015) and −0.33 mmol/liter, 8.2% (P = 0.004), respectively]. Low density lipoprotein cholesterol decrease was more pronounced in patients with TSH levels greater than 12 mIU/liter or elevated low density lipoprotein cholesterol levels at baseline. A significant decrease in apolipoprotein B-100 concentrations was observed (P = 0.037), whereas high density lipoprotein cholesterol, triglycerides, apolipoprotein AI, and lipoprotein(a) levels remained unchanged. Two clinical scores assessing symptoms and signs of hypothyroidism (Billewicz and Zulewski scores) improved significantly (P = 0.02). This is the first double blind study to show that physiological l-thyroxine replacement in patients with subclinical hypothyroidism has a beneficial effect on low density lipoprotein cholesterol levels and clinical symptoms of hypothyroidism. An important risk reduction of cardiovascular mortality of 9–31% can be estimated from the observed improvement in low density lipoprotein cholesterol.